【诺诚健华(09969.HK):fadeucravacitinib (ICP-488)治疗中重度斑块状银屑病的 III期注册性试验成功达到其主要终点】智通财经APP讯,诺诚健华(09969.HK)公布,强效的高选择性酪氨酸激酶2 (TYK2)变构抑制剂fadeucravacitinib
(ICP-488),用于治疗中重度斑块状银屑病患者的III期注册性临床试验成功达到其主要终点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.